INDY as a Therapeutic Target for Cardio-Metabolic Disease.

Abstract

Decreased expression of the plasma membrane citrate transporter INDY (acronym I'm Not Dead, Yet) promotes longevity and protects from high-fat diet- and aging-induced metabolic derangements. Preventing citrate import into hepatocytes by different strategies can reduce hepatic triglyceride accumulation and improve hepatic insulin sensitivity, even in the absence of effects on body composition. These beneficial effects likely derive from decreased hepatic de novo fatty acid biosynthesis as a result of reduced cytoplasmic citrate levels. While in vivo and in vitro studies show that inhibition of INDY prevents intracellular lipid accumulation, body weight is not affected by organ-specific INDY inhibition. Besides these beneficial metabolic effects, INDY inhibition may also improve blood pressure control through sympathetic nervous system inhibition, partly via reduced peripheral catecholamine synthesis. These effects make INDY a promising candidate with bidirectional benefits for improving both metabolic disease and blood pressure control.

• Authors: Dominik Pesta, Jens Jordan
• Journal: Metabolites (Metabolites) Vol. 12 Issue 3 (Mar 14 2022) ISSN: 2218-1989 [Print] Switzerland
• PMID: 35323687 (Publication Type: Journal Article, Review)